New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.

NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD Sergey N. Avdeev Viliya V. Gaynitdinova Qingyun Ma Research Open Access 01 Jul 2025 Scientific Reports Volume: 15, P: 21169 ...

There is a need to re-evaluate the concept of asthma and chronic obstructive pulmonary disease (COPD) as separate conditions, and to consider situations when they may coexist, or when one condition ...